PDL BioPharma (NASDAQ:PDLI) spotted trading -12.60% off 52-week high price. On the other end, the stock has been noted 65.05% away from the low price over the last 52-weeks. The stock changed 0.59% to recent value of $3.4. The stock transacted 2218911 shares during most recent day however it has an average volume of 1.37M shares. The company has 113.85M of outstanding shares and 108.83M shares were floated in the market.

On Feb. 28, 2020, PDL BioPharma (NASDAQ:PDLI) disclosed it has entered into a cooperation agreement with Engine Capital Management LP (together with its affiliates, Engine), which owns approximately 5.5% of the Company’s outstanding shares, pursuant to which Alan L. Bazaar will immediately join PDL’s Board of Directors as a Class III director serving until the Company’s 2022 Annual Meeting of Stockholders.  PDL has also agreed to form a Cost Committee of the Board, chaired by Mr. Bazaar, to oversee cost reduction initiatives and will present a proposal to declassify the Board at the 2020 Annual Meeting.  Following the 2020 Annual Meeting, Mr. Bazaar will be appointed to the Compensation Committee of the Board, and PDL’s Board will be comprised of seven directors, five of whom are independent.  At that time, the Company will have refreshed five of the seven seats on the Board since June 2018.

We are pleased to welcome Alan to PDL’s Board, said Elizabeth O’Farrell, Chairperson of PDL.  Alan has significant experience serving as a director at companies that have undergone successful sale processes.  We believe this experience will benefit PDL and its stockholders as we continue to work expeditiously to monetize our assets and return net proceeds to stockholders.

I am excited to join PDL’s Board at this important juncture and believe there are significant opportunities to realize value, said Mr. Bazaar.  I look forward to collaborating with my fellow directors and the management team as we work to maximize the value of PDL’s assets for the benefit of all stockholders.

Its earnings per share (EPS) expected to touch remained -166.30% for this year while earning per share for the next 5-years is expected to reach at 14.00%. PDLI has a gross margin of 51.10%.

According to the most recent quarter its current ratio was 9.9 that represents company’s ability to meet its current financial obligations. The price moved ahead of -2.49% from the mean of 20 days, 1.63% from mean of 50 days SMA and performed 16.00% from mean of 200 days price. Company’s performance for the week was -2.30%, 1.80% for month and YTD performance remained 4.78%.

Leave a Reply

Your email address will not be published. Required fields are marked *